EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Newsletter

Which scenarios should the board review?

Dose Diligence research deskSection 10 · Page 11 of 15Last updated 17 Nov 2026

The scenarios below are analyst-designed stress tests. No probabilities are assigned.

ScenarioEvidence or trigger to monitorProposed responseExposure to quantify
Scheduled list-price reset occursManufacturer implementation and actual distributor quotationsReconcile contract pricing and inventory treatmentStock exposure, credits and clinic acquisition cost
A patient-access offer changesRevised manufacturer eligibility, price or refill termsRefresh affordability estimates and patient communicationsPatient expenditure, clinic support workload and refunds
A pharmacy pauses new ordersWritten notice or deterioration in agreed performance measuresActivate a pre-screened alternative and reconcile open ordersUnfulfilled prescriptions, deposits and transition work
A proposed compounded route becomes unusableCounsel’s assessment of applicable regulatory or legal developmentsStop new commitments; implement a clinically supervised access transitionMinimum payments, stranded expenditure and communication costs
Bridge processing creates additional reworkAggregate rejection and clarification reasonsCorrect routing and documentation before expanding the workflowStaff minutes per completed case and unresolved patient demand

Board question: What evidence would cause us to pause a route, and who has authority to act? Decide this before the disruption rather than during it.

Explore the table row by row

A working view of the research

Scheduled list-price reset occurs

Evidence or trigger to monitor
Manufacturer implementation and actual distributor quotations
Proposed response
Reconcile contract pricing and inventory treatment
Exposure to quantify
Stock exposure, credits and clinic acquisition cost

Sources cited on this page

    See the section’s source register for the research context.

    Section sources →